Detection of head and neck cancer with tcm glutathione: a correlative study with tissue glutathione and glutathione

Nuclear Medicine Communications

Volumn 22, Issue 1, 2001, Pages 33-38

  CAGLAR, M ^a   CIFTCI I ^b   KilinC K ^b   Ercan, M T ^b  

^a Departments of Nuclear Medicine   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Glutathione; GSH and GST levels; Head and neck cancer; Radionuclide imaging

Indexed keywords

GLUTATHIONE; GLUTATHIONE TRANSFERASE; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GLUTATHIONE METABOLISM; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; MALE; PROTEIN BINDING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR SCINTISCANNING; URINARY EXCRETION;

ADULT; AGED; FEMALE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0035110991     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200101000-00005     Document Type: Article

References (37)

1. Parker SL, Tong T, Bolden S et al. Cancer statistics 1996. CA Cancer J Clin 1996; 46: 5-27.
2. Sham JS, Choy D. Prognostic factors of nasopharyngeal carcinoma: a review of 759 patients. Br J Radiol 1990; 63: 51-58.
3. Snow GB, Annanyas AA, Van Slooten et al. Prognostic factors of neck metastases. Clin Otolaryngol 1982; 7: 185-192.
4. Quetz JU, Rohr S, Hoffmann P et al. B-image sonography in lymph node staging of the head and neck area. A comparison with palpation, computerized and magnetic resonance tomography. HNO 1991; 39: 61-63.
5. Som P. Lymph nodes of the neck. Radiology 1987; 165: 593-600.
6. Hoffer PB, Gottschalk A. Tumor scanning agents. Semin Nucl Med 1974; 4: 305-316.
7. Goodwin DA, Meares CF, De Riemer LH et al. Clinical studies with In-111 BLEDTA, a tumor imaging conjugate of bleomycin with a bifunctional chelating agent. J Nucl Med 1981; 22: 787-792.
8. Kairemo KJA, Hopsu EVM. Imaging of pharyngeal and laryngeal carcinomas with indium-111 labelled monoclonal anti-CEA antibodies. Laryngoscope 1990; 100: 1077-1082.
9. Teates C, Preston DF, Boyd CM. Gallium citrate imaging in head and neck tumors: report of cooperative group. J Nucl Med 1980; 21: 622-627.
10. Laubenbacher C, Saumweber D, Wagner-Manslau et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI, endoscopy for staging head and neck squamous cell carcinomas. J Nucl Med 1995; 36: 1747-1757.
11. Kubota R, Yamada S, Kubota K et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo-high accumulation in macrophages and granulation tissues studied by microautoradiographic comparison with FDG. J Nucl Med 1992; 3: 1972-1980.
12. Adams S, Baum RP, Stuckensen T et al. Prospective comparison of F-18-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 250: 1255-1260.
13. Flamen P, Bernheim N, Deron P et al. Iodine-123 alpha-methyl-L-tyrosine single photon emission tomography for visualisation of head and neck squamous carcinomas. Eur J Nucl Med 1998; 25: 177-181.
14. Haberkorn U, Strauss LG, Reisser C et al. Glucose uptake, perfusion and cell proliferation in head and neck tumors: relation of positron emission tomography and flow cytometry. J Nucl Med 1991; 32: 1548-1555.
15. Haberkorn U, Strauss LG, Dimitrakopoulou A et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993; 34: 12-17.
16. Lindholm P, Minn H, Leskinen-Kallio S et al. Influence of blood glucose concentration on FDG uptake in cancer-a PET study. J Nucl Med 1993; 34: 1-6.
17. Field JK, Lamonthe A, Spondidos DA et al. Clinical relevance of oncogene expression in head and neck tumors. Anticancer Res 1986; 6: 595-600.
18. Field JK, Spandidos DA, Stell PM et al. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989; 4: 1463-1468.
19. Kubota R, Kubota K, Yamada S et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995; 36: 484-492.
20. Braams JW, Pruim J, Nikkels PGJ et al. Nodal spread of squamous cell carcinoma of the oral cavity detected with PET-tyrosine, MRI and CT. J Nucl Med 1996; 37: 897-901.
21. Leskinen-Kallio S, Nagren K, Lehikoinen P et al. Carbon-11 methionine and PET is an effective method to image head and neck cancer. J Nucl Med 1992; 33: 691-695.
22. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-15549.
23. Cowan B, Batist G, Tulpule A, Sinha BK, Myers CE. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 1986; 83: 9328-9332.
24. Ercan MT, Bekdik CF, Şarizi T. Tc-99m glutathione labelling and distribution in rats. Int J Appl Rad Isotopes 1978; 29: 697-698.
25. Burtis CA, Ashwood ER eds. Determination of erythrocyte glutathione concentration. In: Tietz. Textbook of clinical chemistry. Second edition. Philadelphia: Saunders, 1990-1991.
26. Mannervik B, Guthenberg C. Glutathione transferase (human placenta). Meth Enzymol 1981; 77: 231-235.
27. Pauwels EKJ, McCready RV, Stoot JHMB, van Deurzen DFP. The mechanism of accumulation of tumor localizing radiopharmaceuticals. Eur J Nucl Med 1998; 25: 277-305.
28. Arias IM, Jakoby WB. Glutathione: metabolism and function. New York: Raven Press, 1976: 382-392.
29. Muenze R. Technetium-99m radiopharmaceuticals: structure-activity relationship. In: Deckert H, Cox PH, eds. Principles of radiopharmacology. Dordrench: Martinus Nijhoff, 1987: 100-116.
30. Baba K, Moretti JL, Ercan M. Chemical characterization and biodistribution of Tc-99 and Tc-99m glutathione in rats. Eur J Nucl Med 1999; 26: 1194.
31. Ercan MT. Zn-65 glutathione: biodistribution and effect of carrier zinc on pancreas uptake. Int J Appl Rad Isotopes 1981; 32: 417-421.
32. Babich JW. Tc-99m HMPAO retention and the role of glutathione: the debate continues. J Nucl Med 1991; 9: 1681-1683.
33. Ercan MT, Aras T, Aktas, Kaya S, Bekdik CF. Accumulation of Tc-99m glutatione in head and neck tumor. Nucl Med 1994; 33: 224-228.
34. Ercan MT, Unlenen E, Aktas A. Technetium-99m glutathione for imaging inflammatory lesions. Nucl Med Commun 1994; 15: 533-539.
35. Ercan MT, Unlu M, Inanir S, Ilgin N. Tc99m glutathione for imaging arthritic joints in man. Turkish Journal of Nuclear Medicine 1995; 4: 6-10.
36. Coates A, Tripp E. Glutathione content of human malignant melanoma cell lines: correlation of flow cytometric and biochemical assays and application to human tumor aspirates. Melanoma Res 1992; 1: 327-332.
37. Mannarvik B, Castro VM, Danielson UH, Tahir MK, Hansson J, Ringborg U. Expression of class Pi glutathione transferase in human malignant cell. Carcinogenesis 1987; 1: 1929-1932.